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assessors and analysed using mixed-effect models.  Results: 
A total of 49 clinicians and 179 patients were randomised. 
Implementation of DIALOG+ was variable, with an average of 
1.8 sessions (SD = 1.6) in the first 3 months and 1.1 (SD = 1.2) 
in the following 3 months. Patients in the DIALOG+ arm had 
better SQOL at 3, 6 and 12 months (p = 0.035, 0.058 and 0.014, 
respectively; Cohen’s d = 0.29–0.34). They also had signifi-
cantly fewer unmet needs at 3 and 6 months, fewer general 
psychopathological symptoms at all time points and better 
objective social outcomes at 12 months, with no significant 
differences in other outcomes. Overall care costs were lower 
in the intervention group.  Conclusion: Despite variable im-
plementation, DIALOG+ is a beneficial intervention for com-
munity patients with psychosis. As a non-expensive and po-
tentially cost-saving, generic intervention, DIALOG+ may be 
widely used and may improve the effectiveness of commu-
nity treatment. Further trials should test DIALOG+ in different 
patient groups and contexts.  © 2015 S. Karger AG, Basel 
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 Abstract 
 Background: DIALOG+ was developed as a computer-medi-
ated intervention, consisting of a structured assessment of 
patients’ concerns combined with a solution-focused ap-
proach to initiate change. This study tested the effectiveness 
of DIALOG+ in the community treatment of patients with 
psychosis.  Method: This was a pragmatic, exploratory, paral-
lel-group, cluster-randomised controlled trial. Clinicians 
within community teams – along with patients with psycho-
sis under their care – were randomised to use DIALOG+ once 
per month for 6 months or an active control. The primary out-
come (subjective quality of life, SQOL) and secondary out-
comes were assessed after 3, 6 and 12 months by blinded 
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 Introduction 
 Routine meetings between patients and clinicians are 
central to community mental health care. There is little re-
search evidence on how these meetings should be conduct-
ed in order to be therapeutically effective, and there has 
been no evidence-based therapeutic intervention specifi-
cally developed for this context  [1] . The meetings should 
assess all relevant information but also help patients to ini-
tiate change and improve their situation. Interventions for 
inducing change should be based on a therapeutic model 
 [2] . Given the variety of problems and concerns of patients 
with psychosis in the community, a model that strengthens 
and utilises the resources of patients rather than addresses 
specific deficits might be useful. Several such resource-ori-
ented and generic models have been suggested in the lit-
erature. One such model is solution-focused therapy (SFT) 
 [3] . It may be particularly useful to underpin practice in 
community treatment as it can be very brief, is flexible with 
regard to setting and format and provides guidance for in-
dividual problem solving.
 Previous interventions to improve community mental 
health care have attempted to feed back regular patient 
outcome data to clinicians in order to inform their practice 
 [4–6] . These interventions have been found to have little 
effect on patient outcomes, possibly because they fail to 
influence clinician behaviour within meetings. To address 
this issue, a computer-mediated intervention (DIALOG) 
was developed in which patients rate their satisfaction and 
needs for care on 8 life domains and 3 treatment aspects 
within the routine meetings  [7] . This assessment provides 
a structure to the meetings and aims to make them patient 
centred and focused on change. DIALOG was tested in a 
cluster-randomised controlled trial with community pa-
tients with psychosis in six European countries over 1 year. 
Patients receiving DIALOG had significantly better sub-
jective quality of life (SQOL), fewer unmet treatment needs 
and higher treatment satisfaction  [7] .
 Though the DIALOG intervention implements a 
structured patient assessment, it does not provide any 
guide for clinicians on how to respond to patients’ rat-
ings. To address this, a brief psychological intervention 
informed by the principles of SFT has been developed. It 
is based on the following: (1) experiences with DIALOG 
in practice; (2) consultations with clinicians in commu-
nity mental health teams and leading practitioners in 
SFT, and (3) focus groups with patients. A 4-step ap-
proach provides a guide for dealing with the specific con-
cerns raised by the patient and equips the clinician, as well 
as the patient, with a method to explore and address the 
identified problems and wishes. The new intervention 
‘DIALOG+’ combines the original computer-mediated 
DIALOG assessment with this 4-step approach. The in-
tention is to structure the patient-clinician communica-
tion so that there is a patient-centred and comprehensive 
assessment of patients’ views and concerns followed by a 
discussion that leads to solutions and helps patients to 
adopt a model of problem solving. The hypothesis is that 
such interventions will initiate and monitor change.
 The aim of this pragmatic trial was to investigate 
whether the DIALOG+ intervention, used about once a 
month over 6 months with patients with psychosis in rou-
tine community mental health meetings, is associated 
with positive changes in patients’ quality of life and other 
favourable outcomes compared with an active control 
condition. The active control administered the same 
computer-mediated ratings but at the end of the meeting 
and without any further discussion. This was to control 
for the novelty of using an electronic device in the clinical 
setting, the addition of a regular assessment to routine 
meetings and the same repeated ratings of satisfaction.
 Method 
 Study Design 
 The study was a pragmatic, parallel-group, cluster-random-
ised controlled trial. A detailed description of the methodology
can be found in the protocol (Current Controlled Trials No.
ISRCTN34757603)  [8] . 
 Clusters were clinicians working in community mental health 
teams in London, UK. Clinicians were randomly assigned to either 
the DIALOG+ intervention or the control condition, with an al-
location ratio of 1: 1. A cluster-randomisation design was used to 
avoid potential contamination of the practice of clinicians when 
treating patients in both groups.
 Participants and Settings 
 The study was conducted in seven community mental health 
teams across East London. All teams were multidisciplinary and 
provided care for people with severe mental illnesses of working 
age. In these teams every patient has a dedicated clinician respon-
sible for care coordination, with whom they meet at least once a 
month. These clinicians are qualified mental health professionals, 
mostly psychiatric nurses, often referred to as care coordinators or 
keyworkers. They are the main contacts for patients and may ar-
range further input of other clinicians if and as required. 
 To reflect the pragmatic approach of the trial, teams and partici-
pating clinicians within teams were identified by the management of 
the provider organisation (East London NHS Foundation Trust). 
Clinicians were eligible if they had a professional qualification, more 
than 6 months’ experience of working in community mental health 
care and no plans to leave their post within the study period. 
 The caseloads of participating clinicians were screened to iden-
tify eligible patients. Inclusion criteria for patients were as follows: 
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age 18–65 years; treatment in the community team for at least 1 
month; no planned discharge for the next 6 months; a clinical di-
agnosis of schizophrenia or a related disorder (ICD-10 F20–29), 
and capacity to give informed consent. Patients were excluded if 
they had a mean score of 5 or higher on the Manchester Short As-
sessment of Quality of Life (MANSA)  [9] , reflecting an average 
rating of at least ‘mostly satisfied’ with all life domains, and if they 
had insufficient command of English for conducting meetings in 
English. Initially, a random sample of 7 eligible patients from each 
clinician was approached. If less than 5 consented, additional eli-
gible patients were approached in a predefined random order. Re-
cruitment took place between October 2012 and September 2013.
 Written informed consent was obtained from all clinicians and 
patients. The study received a favourable opinion from the Re-
search Ethics Committee (Stanmore; 12/LO/1145).
 Interventions 
 Experimental Condition 
 In the experimental group, clinicians and patients were in-
structed to use DIALOG+ once per month over a 6-month period, 
as clinicians are expected to meet patients at least once a month in 
these services. However, it was acknowledged that this could vary 
in practice. After 6 months, clinicians and patients could continue 
the intervention if they wished. DIALOG+ was delivered using a 
tablet computer, which could be shared between clinician and pa-
tient throughout the conversation (for screenshots, see online sup-
pl. 1; see www.karger.com/doi/10.1159/000430991 for all online 
suppl. material).
 Each DIALOG+ session begins with the same assessment of 
topics as in the original DIALOG intervention, whereby patients 
are asked to rate their satisfaction with 8 life domains (mental 
health, physical health, job situation, accommodation, leisure ac-
tivities, friendships, relationship with family/partner, personal 
safety) and 3 treatment aspects (medication, practical help, meet-
ings with professionals). Each satisfaction item is rated on a scale 
from 1 (‘totally dissatisfied’) to 7 (‘totally satisfied’) and followed 
by a question on whether the patient wants additional help in the 
given domain. The ratings are then summarised on the screen, al-
lowing for comparisons with previous ratings. Clinicians are in-
structed to offer positive feedback on any improving or high-scor-
ing domains. The summary is then used to inform a joint decision 
about which domains should be discussed in greater depth.
 Each of the domains chosen for further discussion are ad-
dressed in a 4-step approach informed by the principles of SFT: (1) 
understanding the patient’s concerns and previous effective cop-
ing strategies; (2) identifying best-case scenarios and smallest steps 
for improvement; (3) exploring options available to the patient, 
including the patient’s own resources, the clinician’s and those of 
others in the patient’s life, and finally, (4) agreeing on actions to 
address the identified concerns. Agreed actions are later reviewed 
at the start of the following meeting. 
 All clinicians in the experimental group received a half-day 
one-to-one training. The first and 1 subsequent DIALOG+ session 
for each patient were audio-recorded and feedback provided. The 
manual is available from the authors on request.
 Control Condition 
 In the control condition, patients conducted the same ratings 
using the devices and software but at the end of the meetings, in-
dependently rather than collaboratively, and without further dis-
cussion. This was to control for the novelty factor and to ensure 
that potential effects on SQOL were not influenced by more fre-
quent ratings in the intervention group.
 Outcomes 
 All outcomes were prespecified and measured at baseline and 
at the 3-, 6- and 12-month follow-ups.
 Baseline Characteristics 
 Information on the gender, ethnicity, age, marital status, edu-
cation level, admission history, length of relationship with clini-
cian, and primary diagnosis was collected at baseline. The primary 
diagnosis was obtained from the electronic patient record system 
and was based on the latest psychiatric assessment.
 Primary Outcome 
 The primary outcome was SQOL, which was measured as the 
mean score on the MANSA  [9, 10] . On 12 Likert-type scales, pa-
tients rate their satisfaction with different life domains from 1 
(could not be worse) to 7 (could not be better). This has been wide-
ly used in research with community patients  [11] .
 Secondary Outcomes 
 The number of unmet needs was self-assessed on the Camber-
well Assessment of Need Short Appraisal Schedule (CANSAS)  [12, 
13] , with ratings in 22 domains. Treatment satisfaction was self-
rated on the Client Satisfaction Questionnaire (CSQ-8)  [14, 15] , 
with 8 items and higher scores indicating greater satisfaction. Self-
efficacy was self-rated on the 10-item General Self-efficacy Scale 
(GSS)  [16, 17] , with higher scores reflecting higher self-efficacy. 
Mental well-being was self-assessed on the 14-item Warwick-Ed-
inburgh Mental Well-Being Scale (WEMWBS)  [18, 19] , with high-
er scores indicating better well-being. Psychopathological symp-
toms were observer rated using the 30-item Positive and Negative 
Syndrome Scale (PANSS)  [20, 21] , which provides scores for pos-
itive symptoms (ranging from 7 to 49), negative symptoms (from 
7 to 49) and general symptoms (from 16 to 112). The therapeutic 
relationship was assessed on the Scale for Assessing Therapeutic 
Relationships in Community Mental Health Care, patient version 
(STAR-P) and clinician version (STAR-C)  [22] . Both scales have 
12 items, with higher scores indicating a stronger relationship. So-
cial outcomes were assessed using the Objective Social Outcomes 
Index (SIX)  [23] , which obtains objective data on employment sta-
tus, accommodation status, living situation, and social contacts 
and provides a total score from 0 to 6 (higher scores reflect a more 
positive social outcome). 
 All outcomes were collected in one-to-one meetings between a 
researcher and a patient, with researchers guiding patients through 
self-report measures and using structured interviews for the 
PANSS. The only exception was the STAR-C, which was indepen-
dently self-rated by clinicians. A total of 6 researchers were in-
volved in the assessment of outcomes. Interrater reliability for the 
PANSS between the 6 researchers was good (intraclass correlation 
coefficient = 0.828).
 Cost-Effectiveness Outcomes 
 The costs of care were recorded using the Client Service Receipt 
Inventory (CSRI)  [24] , which records patients’ use of health and 
social care services, including hospital services, community and 
outpatient services, and medication. These data were collected ret-
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rospectively for the 3 months prior to each time point (baseline 
and 3, 6 and 12 months). The data were collected through patient 
self-report supplemented by the clinical notes from the patient 
electronic record system to improve accuracy.
 Sample Size 
 We aimed to recruit 36 clinicians and 180 patients, with 18 cli-
nicians and 90 patients in each condition (5 patients per clinician). 
We anticipated the loss of 6 clinicians and 30 of their patients due 
to unexpected job changes. With a patient dropout rate of less than 
10%, we would end with a sample of 136 patients. Assuming a prac-
tically negligible cluster effect (as in the original DIALOG trial), 
the sample size would be sufficient to detect a medium effect size 
with 80% power at the 5% significance level. 
 During the recruitment phase, the sample size as described in 
the protocol was increased from 36 clinicians to 49, as a lower 
number of patients per clinician were being recruited than expect-
ed. This did not change the target sample size of patients. 
 Randomisation  
 An independent statistician allocated clinicians to the experi-
mental or control conditions according to a computer-generated 
randomisation list. The randomisation sequence was created using 
random block sizes of 4 and 6. Randomisation was not stratified, 
as all clusters (clinicians) had similar experience and patient case-
loads. 
 To minimise selection bias within clusters, clinicians were ran-
domised once all patients from their caseload had been recruited 
and all baseline assessments were completed. The allocation of 
clusters was concealed from outcome assessors, and clinicians 
were asked to keep their treatment allocation concealed from their 
colleagues and managers. 
 Blinding 
 The principal investigator, all 6 outcome assessors and the data 
analysts were blinded to the clinicians’ and patients’ allocations. 
Although it was not possible to blind patients to the treatment al-
location, those in the control group were still required to complete 
the same assessments on a tablet computer, and it was not made 
explicit whether they were receiving the experimental intervention 
or not. If blinding was compromised during the interviews, a dif-
ferent researcher conducted the next follow-up assessment. 
 Statistical Analysis 
 An analysis plan was drafted and signed off prior to any un-
blinding and analysis taking place. All analyses were conducted 
two sided and significance interpreted at the 5% level. 
 Available Case Analysis 
 The main analysis was conducted at the level of the individual 
and based on available cases, following intention-to-treat princi-
ples. The analysis of continuous outcomes was conducted using a 
generalised linear model, with a fixed effect for treatment and the 
associated baseline value of the outcome and a random effect for 
clinician to account for clustering. Cohen’s d was derived from raw 
data and calculated for significant results of continuous variables 
as a standardised effect size measure. The number of unmet needs 
(CANSAS) was analysed using a Poisson regression, with treat-
ment and baseline unmet needs fitted as fixed effects and clinician 
fitted as a random effect. The analysis of objective social outcomes 
(SIX) was conducted using a proportional odds model with ran-
dom intercept, with treatment fitted as a fixed effect and clinician 
fitted as a random effect. The software used was Stata version 12.1.
 Further Analyses 
 Two further analyses were conducted on the primary outcome. 
 To address the potential bias of the available case analysis due to 
attrition, a linear mixed effects model was conducted with MAN-
SA scores at all time points as the dependent variable. The model 
included a random effect of cluster and, within clusters, cross-clas-
sified random effects of time and patient. A likelihood-based anal-
ysis of this kind provides an unbiased estimate of the treatment 
effect under the assumption that data are missing at random con-
ditional on the included data.
 A per protocol analysis was also carried out on MANSA scores, 
using the same methods as the available case analysis but including 
only those patients who received 2 or more DIALOG+ sessions or 
control sessions, respectively. At least 1 repeat session was consid-
ered essential to capture the key elements of the intervention.
 Cost-Effectiveness Analysis 
 The extra intervention costs of DIALOG+ included specific 
training of staff and the tablet computer (GBP 109 per patient). 
The cost of the tablet computer in the control group was not in-
cluded as it was designed to control for non-specific effects. Service 
use as measured on the CSRI was combined with the relevant unit 
costs  [25, 26] . The total costs over 12 months were then calculated 
based on the CSRI at 3, 6 and 12 months, plus an average of the 6- 
and 12-month costs (as no 9-month follow-up was conducted).
 The total costs of the two groups were compared using a boot-
strapped regression model (to account for a non-normal distribu-
tion) and controlling for baseline costs. Cost-effectiveness was as-
sessed by combining the total costs with the MANSA change 
scores. Uncertainty around the point estimates was addressed by 
generating 1,000 incremental cost-outcome combinations using 
bootstrapping methods and plotting these onto a cost-effective-
ness plane. This allowed for a calculation of the probabilities of the 
intervention saving or increasing costs and improving or worsen-
ing outcomes. 
 Results 
 Participant Flow 
 The CONSORT diagram summarising the flow of par-
ticipants throughout the study and the reasons for ex-
cluding clinicians and patients is contained in online sup-
plement 2.
 A total of 59 clinicians and 709 of their patients were 
assessed for eligibility. Following baseline assessments, 
the 49 eligible clinicians and their 188 patients were ran-
domly assigned to the DIALOG+ or control condition. Of 
the 188 participating patients, 9 either withdrew from the 
study or were discharged from the clinician’s case load 
prerandomisation, though the research team did not learn 
of this until after the randomisation had taken place. As a 
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result they were deemed as ‘randomised in error’ and ex-
cluded from the analysis. Thus, 49 eligible clinicians and 
179 patients were correctly assigned to the DIALOG+ in-
tervention (clinicians: n = 25; patients: n = 94) or the con-
trol condition (clinicians: n = 24; patients: n = 85).
 Overall, 4 clinicians (3 experimental; 1 control) with-
drew from the study, and their patients (11 experimental; 
3 control) did not receive the allocated intervention. In 
the DIALOG+ intervention group, 1 further clinician 
withdrew from the study; however, the patients (n = 2) 
received the intervention from another included clini-
cian. The primary outcome was assessed in 120/179 pa-
tients at 3 months (67%; 61 experimental, 59 control), 
147/179 at 6 months (82.1%; 73 experimental, 74 control) 
and 129/179 at 12 months (72.1%; 61 experimental, 68 
control).
 Implementation 
 The implementation of the DIALOG+ intervention 
was variable. Data on the number of sessions delivered 
were obtained for 80 patients (data were missing for 14). 
Of these, 24 (30%) did not have any DIALOG+ sessions 
with their clinician. This was because the clinician with-
drew from the study (n = 11), the patient withdrew from 
the study (n = 7) or no DIALOG+ sessions took place 
within the intervention period (n = 6). Overall, patients 
allocated to the DIALOG+ arm had on average of 1.8 
sessions (SD = 1.6) in the first 3 months and 1.1 (SD = 
1.2) in the second 3-month period. Of the patients who 
received at least 1 DIALOG+ session, the intervention 
was delivered on average 2.6 times (SD = 1.3) in the first 
3 months and 1.5 times (SD = 1.1) in the second 3 
months, with a total mean number of 4.1 sessions
 Table 1.  Baseline characteristics of patients
Characteristics Intervention group 
(n = 94)
Control group 
(n = 85)
Total 
(n = 179)
Gender
Female 28 (30) 28 (33) 56 (31)
Male 66 (70) 57 (67) 123 (69)
Ethnicity
White 23 (25) 23 (27) 46 (26)
Black 38 (40) 32 (38) 70 (39)
Asian 28 (30) 21 (25) 49 (27)
Mixed/other 5 (5) 9 (11) 14 (8)
Age, years 41.5 ± 10.7 41.7 ± 9.3 41.6 ± 10.1
Marital status
Single 75 (80) 71 (84) 146 (82)
Married 19 (20) 14 (17) 33 (18)
Highest level of education
None (left prior to compulsory education) 26 (28) 22 (26) 48 (27)
Compulsory education (age 16) 27 (29) 25 (29) 52 (29)
Postcompulsory education 40 (43) 38 (45) 78 (44)
Number of previous psychiatric admissions1 2.0 (1 – 4) 2.0 (1 – 5) 2.0 (1 – 4)
Length of relationship with keyworker (years) 1.0 (0 – 2) 1.5 (1 – 2) 1.3 (1 – 2)
Length of contact with services (years) 11.5 (7 – 19) 12.0 (7 – 19) 12.0 (719)
Primary diagnosis (ICD-10)
Schizophrenia (F20) 76 (81) 65 (76) 141 (79)
Delusional disorders (F22) 0 2 (2) 2 (1)
Schizoaffective disorders (F25) 14 (15) 10 (12) 24 (13)
Unspecified non-organic psychosis (F29) 4 (4) 0 4 (2)
Bipolar disorder (F31)2 0 4 (5) 4 (2)
Major depressive episode (F32, F33)2 0 4 (5) 4 (2)
 Values are n (%), mean ± SD or median (with interquartile range), as appropriate.
1 All admissions to psychiatric hospitals for longer than 24 h.
2 The primary diagnosis for 8 patients changed after eligibility screening. However, this information was not 
identified until after randomization, so they remained in the trial and were included in the analysis.
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(SD = 1.9). Only 6 patients continued to use the DIA-
LOG+ intervention with their clinician after the 
6-month follow-up, with an average of 1.2 (SD = 0.4) 
additional sessions. 
 Out of the 85 patients in the control group, 7 did not 
complete any ratings (8%). This was because the clinician 
went on sabbatical (n = 3), the clinician did not deliver 
the control intervention (n = 3) or the patient withdrew 
from the study (n = 1). Those who completed at least one 
rating had on average 4.2 (SD = 1.8) ratings overall, with 
2.6 (SD = 1.1) in the first 3 months and 1.7 (SD = 1.3) in 
the second 3 months.
 Baseline Characteristics of Participants 
 The clinical and sociodemographic characteristics of 
the patients are shown in  table 1 .  Patients were predomi-
nantly male and single, from a wide range of ethnicities. 
In 8 patients in the control group, the primary clinical 
diagnosis changed before randomisation. However, the 
research team did not learn of this until after randomisa-
tion and, therefore, they were included in the analysis. A 
total of 14 clinicians (56%) in the experimental group and 
15 (63%) in the control group were female.
 Blinding 
 Blinding was compromised for 2 interviewers in a total 
of 3 cases, where the interviewer identified the allocation 
of a patient (1 at the 3-month follow-up, 2 at 6 months 
and none at the 12-month follow-up).
 Primary Outcome 
 The results for all outcomes are summarised in  table 2 . 
 At the 3-month follow-up, SQOL (MANSA) was signifi-
cantly higher in the experimental group (effect size: Co-
hen’s d = 0.34). At the 6-month follow-up, there was a 
trend towards higher SQOL in the experimental group
(d = 0.29). This effect remained significant at the 12-month 
follow-up (d = 0.34).
 Further Analyses 
 The further analyses provided similar results.  The lin-
ear mixed effects model, with MANSA scores at all time 
points as the dependent variable, showed slightly lower 
adjusted mean differences, i.e. 0.24, 0.26 and 0.26 after 3, 
6 and 12 months (p = 0.059, 0.028 and 0.034, respective-
ly) versus 0.30, 0.26 and 0.32 in the available case analy-
sis. The adjusted mean differences in the per protocol 
analysis were also similar, i.e. 0.25, 0.32 and 0.32 after 3, 
6 and 12 months (p = 0.178, 0.030 and 0.034, respective-
ly). 
 Secondary Outcomes 
 There were significantly fewer unmet needs (CANSAS)
in the experimental group at 3 and at 6 months. The effect 
reflects an absolute difference of 1.0 need at 3 months and 
1.1 needs at 6 months. The level of general psychopatho-
logical symptoms was significantly lower in the experi-
mental group at 3 months (effect size: d = 0.55), 6 months 
(d = 0.54) and 12 months (d = 0.65).
 There was no significant difference on objective social 
outcomes (SIX) at 3 months (d = 0.21)  and 6 months
(d = 0.30). However, patients in the experimental group 
had significantly better objective social outcomes at the 
12-month follow-up (d = 0.50). No statistically significant 
differences between the treatment groups were found in 
any of the other secondary outcomes at any time point. 
 Cost-Effectiveness 
 The mean total costs over 12 months were lower in the 
experimental group (GBP 3,279) than the control group 
(GBP 4,624). This amounted to a cost saving of GBP 1,288 
after controlling for baseline costs (bootstrapped 95% 
confidence interval: GBP –1,318 to GBP 5,633). There is 
a 72.4% probability of the intervention both improving 
outcomes and saving costs. The probability of the inter-
vention being more effective at a higher cost is 26.5%.
 Discussion 
 Main Findings 
 DIALOG+ had a positive effect in the community 
treatment of patients with psychosis. SQOL was already 
improved after 3 months. The effect was still apparent at 
12 months (6 months after, all but 6 patients had stopped 
the intervention). Different types of analyses provided 
similar results. The number of unmet needs was signifi-
cantly reduced after 3 months and at 6 months. This is 
in line with the intention of DIALOG+ to identify and 
address the concerns and unmet needs of patients. There 
were also significant benefits on general psychopatho-
logical symptoms and objective social outcomes after 12 
months only, and the intervention is likely to be cost 
saving. There was no effect on other secondary out-
comes.
 Strengths and Limitations 
 A key strength is the pragmatic nature of the trial. The 
intervention was implemented in routine services as it 
would be rolled out in practice, and the results are there-
fore likely to be generalisable to other routine services. 
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 Table 2.  Primary and secondary outcomes at baseline and at 3, 6 and 12 months
Outcome Intervention group  Control group β 
coefficient
95% CI p value ICC
n mean ± SD  n mean ± SD
Quality of life (MANSA)
Baseline 94 4.0 ± 0.9 85 3.8 ± 0.9
3 months 61 4.4 ± 0.9 59 4.1 ± 0.9 0.299 0.021 to 0.578 0.035 <0.001
6 months 73 4.3 ± 1.0 74 4.0 ± 1.0 0.257 –0.009 to 0.524 0.058 <0.001
12 months 61 4.4 ± 0.9 68 4.1 ± 0.9 0.319 0.063 to 0.575 0.014 <0.001
Treatment satisfaction (CSQ-8)
Baseline 93 24.0 ± 4.8 85 23.9 ± 5.5
3 months 61 23.4 ± 5.1 58 24.2 ± 5.3 –0.860 –2.325 to 0.606 0.25 0.037
6 months 73 24.2 ± 5.4 71 23.8 ± 6.0 0.436 –0.956 to 1.827 0.54 <0.001
12 months 61 24.4 ± 5.0 65 23.6 ± 6.0 0.730 –0.800 to 2.260 0.350 <0.001
Self-Efficacy (GSS)
Baseline 91 25.6 ± 7.4 85 25.9 ± 6.6
3 months 61 25.8 ± 6.9 57 26.9 ± 6.6 –1.458 –3.347 to 0.432 0.131 <0.001
6 months 73 26.5 ± 6.6 73 26.5 ± 6.2 –0.162 –1.848 to 1.525 0.851 <0.001
12 months 60 27.0 ± 7.0 65 27.1 ± 6.1 0.231 –1.604 to 2.065 0.805 <0.001
Well-being (WEMWBS)
Baseline 93 43.0 ± 10.6 84 41.7 ± 9.9
3 months 61 43.4 ± 10.9 59 42.5 ± 10.6 0.025 –0.165 to 0.214 0.799 <0.001
6 months 73 43.8 ± 11.5 73 42.8 ± 10.0 0.030 –0.157 to 0.217 0.753 <0.001
12 months 61 45.8 ± 11.2 65 43.8 ± 10.4 2.005 –0.802 to 4.811 0.162 <0.001
Positive symptoms (PANSS-positive)
Baseline 93 14.8 ± 5.7 84 15.1 ± 6.4
3 months 61 14.1 ± 5.6 58 14.0 ± 5.3 0.206 –1.102 to 1.514 0.757 <0.001
6 months 73 13.2 ± 5.2 73 14.4 ± 5.7 –0.927 –2.432 to 0.579 0.228 0.065
12 months 60 12.8 ± 5.3 65 14.3 ± 5.3 –1.459 –3.003 to 0.086 0.064 <0.001
Negative symptoms (PANSS-negative)
Baseline 94 17.1 ± 6.4 84 18.0 ± 7.8
3 months 61 15.2 ± 5.7 58 16.9 ± 6.6 –0.923 –2.692 to 0.846 0.306 <0.001
6 months 73 15.1 ± 5.8 73 15.7 ± 6.1 0.037 –1.591 to 1.665 0.965 <0.001
12 months 60 13.3 ± 5.1 65 15.3 ± 6.3 –1.470 –3.364 to 0.423 0.128 0.208
General symptoms (PANSS-general)
Baseline 93 32.9 ± 8.3 84 34.6 ± 10.1
3 months 61 29.2 ± 8.8 58 34.2 ± 9.2 –3.415 –6.335 to –0.495 0.022 0.189
6 months 73 28.0 ± 9.2 73 32.8 ± 8.9 –4.041 –6.82 to –1.263 0.004 0.079
12 months 60 26.4 ± 7.7 65 31.3 ± 7.3 –4.271 –6.712 to –1.829 0.001 0.067
Therapeutic relationship (STAR-P)
Baseline 93 33.2 ± 8.0 85 34.4 ± 8.2
3 months 56 34.2 ± 8.0 59 33.3 ± 8.8 1.219 –1.102 to 3.539 0.303 <0.001
6 months 66 33.9 ± 8.7 70 32.2 ± 10.4 2.114 –0.67 to 4.897 0.137 0.113
12 months 48 33.0 ± 9.7 56 32.8 ± 9.3 0.448 –2.712 to 3.607 0.781 <0.001
Therapeutic relationship (STAR-C)
Baseline 77 40.8 ± 5.2 83 41.3 ± 4.4
3 months 52 39.8 ± 4.8 54 40.6 ± 4.7 –0.033 –2.341 to 2.276 0.978 0.557
6 months 66 40.8 ± 4.7 66 41.7 ± 5.2 –0.971 –3.203 to 1.262 0.394 0.41
12 months 39 40.2 ± 4.4 47 41.8 ± 4.9 –2.454 –5.108 to 0.200 0.070 0.536
Unmet needs (CANSAS)
Baseline 94 3.5 ± 3.1 85 3.9 ± 2.9
3 months 61 2.2 ± 2.2 59 3.2 ± 3.1 0.679 0.485 to 0.951 0.024 0.018
6 months 73 2.0 ± 2.9 73 3.1 ± 3.0 0.607 0.412 to 0.895 0.012 0.033
12 months 61 2.0 ± 2.3 66 2.7 ± 2.9 0.732 0.480 to 1.115 0.146 0.045
Social outcomes (SIX)
Baseline 93 2.8 ± 1.0 85 2.6 ± 0.9
3 months 61 2.9 ± 1.3 59 2.7 ± 0.8 0.97 0.39 to 2.44 0.95 <0.001
6 months 73 2.9 ± 1.1 74 2.6 ± 0.9 1.34 0.72 to 2.49 0.358 <0.001
12 months 61 3.1 ± 1.0 68 2.6 ± 0.9 2.91 1.225 to 6.911 0.016 0.149
 Outcome: all outcomes were analysed using random effects linear regres-
sion, with treatment and baseline score fitted as fixed effects and clinician 
fitted as a random effect. Unmet needs (CANSAS): assessed using a Poisson 
regression, with treatment and baseline unmet needs fitted as fixed effects 
and clinician fitted as a random effect (incidence rate ratio used instead of β 
coefficient). SIX score: analysed using a proportional odds model, with treat-
ment fitted as fixed effects and clinician fitted as a random effect (propor-
tional odds ratio used instead of β coefficient). Reported intracluster coeffi-
cient is on the logistic scale. CANSAS: patient-rated version. ICC = Intra-
cluster coefficient.
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However, the pragmatic approach also contributed to the 
variable implementation. A total of 30% of patients in the 
experimental group never received an intervention at all. 
 Further strengths are that the inclusion criteria for pa-
tients were wide, the trial had an active control condition, 
the control intervention was delivered with a similar fre-
quency to the experimental one, and outcome assessors 
were blinded towards the allocation of patients. 
 The study also has several limitations beyond the in-
consistent implementation of the intervention. Clinicians 
could not be blinded towards their own allocation, which 
raises the possibility of performance bias. The study also 
excluded patients who had an insufficient command of 
English, already had a high SQOL at baseline or were 
deemed too unwell to provide informed consent. If the 
intervention is to be rolled out in routine care, such pa-
tients will have to be included, and it remains unclear as 
to what extent the findings of this study would apply to 
the excluded groups. The primary diagnosis was also as-
sessed based on clinical notes. Structured interviews may 
have been more reliable, although the intervention is not 
diagnosis specific. The dropout rate was higher than ex-
pected  [8] . Finally, the sample size was too small to detect 
small effect sizes with sufficient power, although such ef-
fects may still be relevant.
 Interpretation of the Results 
 The findings are consistent and expand the results of the 
original DIALOG trial  [7] . What is common to the original 
DIALOG assessment and the extended DIALOG+ inter-
vention is that they provide a structured, comprehensive 
assessment in routine meetings that is patient centred and 
explores wishes for change. Indeed, a positive change to 
patients’ self-reported needs has been found to be a stron-
ger predictor of improved SQOL than clinician-perceived 
needs  [27] , which highlights the importance of a patient-
centred assessment in routine meetings. 
 DIALOG+ is intended to be more intensive and im-
prove treatment outcomes even if patients do not stay in 
care for a year or more as in the original DIALOG trial. 
Whilst in the original DIALOG intervention clinicians 
were expected to respond to patients’ concerns, there 
were no instructions on how to do this. DIALOG+ pro-
vides such instructions and goes beyond facilitating a 
mere assessment. It guides clinicians in their response to 
the concerns of patients, helping to reach agreements on 
actions in a shared discussion. The 4-step approach in 
DIALOG+ is based on principles of SFT, which has been 
found to be effective in treating a wide range of disorders 
 [28, 29] , requires a shorter time span than alternative 
models  [28] and utilises the patient’s personal and social 
resources rather than being deficit focused  [3, 30] .
 This study did not find a benefit on treatment satisfac-
tion and failed to demonstrate significant effects on fur-
ther patient-reported outcomes such as mental well-be-
ing and self-efficacy. Whilst this may be seen as disap-
pointing, it clarifies that the positive impact on SQOL and 
self-rated unmet needs is not just a generalised more pos-
itive appraisal across all patient-rated outcomes  [31] . The 
effect seems to be more specific and is not primarily 
linked to a non-specific effect of the therapeutic relation-
ship either. In fact, the quality of the therapeutic relation-
ships did not significantly differ between the experimen-
tal and control groups.
 The intervention did improve general psychopatho-
logical symptoms, which may be more closely associated 
with immediate problems and concerns than are positive 
or negative symptoms, on which there was no effect. The 
positive effect on SQOL and general symptoms remained 
at 12 months (6 months after all, but 6 patients had 
stopped using the intervention), suggesting long-term 
benefits for patients. Furthermore, patients in the
DIALOG+ arm had significantly better objective social 
outcomes at the 12-month follow-up. Such outcomes, 
which include employment and housing situation, take 
much longer periods of time to improve. This further 
supports the specific effect of DIALOG+ in initiating real 
change in the patient’s life. 
 After 3 months and on average 2–3 meetings DIALOG+
already had an effect. One may assume that the interven-
tion effectively helps patients and clinicians to identify 
concerns as well as possible solutions and actions during 
the initial 2 or 3 sessions, producing a visible benefit after 
a short period of time. Once this has happened, mere rep-
etitions within the subsequent months may not be of 
much further benefit. Thus, DIALOG+ is likely to be a 
generic short-term intervention – with a lasting effect, 
however. Rather than being frequently applied in regular 
short intervals, it might be used more flexibly and repeat-
ed once the situation of the patient has changed or new 
problems have arisen.
 The effect size on SQOL is equivalent to more positive 
quality of life ratings in at least 3 out of 12 life domains on 
the MANSA, which should be regarded as a clinically sig-
nificant improvement. The effect is greater than in the 
original DIALOG trial (adjusted mean difference on the 
MANSA of 0.30 vs. 0.12), which provided the assessment 
without the ‘plus’ part of DIALOG+, assessed outcomes 
after 1 year, had no active control, and used unblinded as-
sessors of outcomes. The effect size is similar to those re-
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ported for much more extensive and costly psychological 
treatments such as cognitive behaviour therapy  [32–34] . 
One can only speculate as to why DIALOG+ as such a 
brief intervention has a similar effect to more time-con-
suming and cost-intensive therapies. Unlike other thera-
pies, DIALOG+ does not require the referral of a patient 
to a different clinician or service. It is used within the ex-
isting patient-clinician relationship. This may facilitate 
mutual trust and credibility and support the delivery of 
the agreed actions. Another potential advantage is that cli-
nician and patient address practical issues as well as psy-
chological ones, which may have a tangible impact on the 
patient’s life. This may in turn help to alleviate general 
psychopathological symptoms, on which the intervention 
showed a medium-sized beneficial effect, and lead to lon-
ger-term improvement on objective social outcomes.
 Implications and Future Directions 
 Given that this is a low-cost, potentially cost-saving 
and generic intervention which requires limited training 
and no service reorganisation, it is easy to carry out. 
When it is used on a larger scale, small effect sizes in in-
dividual patients would add up to substantial public 
health gains. Using the intervention in practice will also 
deliver, quasi as a side effect, patient-reported outcome 
measures. The scores of the scale in DIALOG and
DIALOG+ have been shown to be valid indicators of 
SQOL and treatment satisfaction  [35] . Obtaining such 
outcomes in a clinically meaningful procedure may be 
more economical and provide better response rates than 
separate assessments purely for evaluation purposes.
 The findings from this pragmatic trial suggest that
DIALOG+ may be used widely in community care. The 
results may also encourage further attempts to use psy-
chological models for making routine meetings in com-
munity mental health care therapeutically more effective 
 [2] . Computer technology like that in DIALOG+ may 
support such attempts but is not the essence of the inter-
vention, as demonstrated by the active control. At the 
heart of the effective intervention is a structured patient-
clinician communication which identifies patients’ con-
cerns, analyses them, finds appropriate solutions in a col-
laborative way, and, hence, initiates change. 
 Further research should test DIALOG+ outside Lon-
don and in different clinical settings and with different 
patient groups. If used in different contexts, the interven-
tion might be further adapted and refined. 
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